Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
1,296 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Role of Selected Myokines and Mineral Metabolism in Spinal Muscular Atrophy: A Systematic Review.
Gryczyńska W, Gajewska E, Steinborn B, Skrypnik D. · FASEB J · 2026 · cited 0 timesOpen accesssystematic review, review-article
- Dietitian-Led Synchronous and Asynchronous Tele-Nutrition in Children With Spinal Muscular Atrophy: A Three-Arm Randomized Controlled Trial.
Muslu M, Gökçay GF. · J Hum Nutr Diet · 2026 · cited 0 timesrandomized controlled trial
- Spinal Muscular Atrophy, Sleep-Disordered Breathing, and the Effects of Disease-Modifying Therapies: A Narrative Review.
Surí-Báez CA, Kitada R, Lester J, Laureta EC, Kelly-Pieper K, Grigg-Damberger M, Kothare SV. · Pediatr Neurol · 2026 · cited 0 timessystematic review
- Sleep phenotypes and respiratory disturbances in spinal muscular atrophy: A systematic review of clinical evidence.
Gnazzo M, Baldini V, Varallo G, Pisanò G, Biscarini F, Carotenuto M, Pizza F, Fiorillo A, Pera MC, Plazzi G. · Sleep Med · 2026 · cited 1 timessystematic review
- High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.
Finkel RS, Crawford TO, Mercuri E, Sumner CJ, Garcia Romero MDM, Day JW, Montes J, Sun P, Tichler B, Paradis AD, Boesch E, Inra J, Littauer R, Sohn J, Monine M, Gambino G, Foster R, Farewell R, Fradette S. · Nat Med · 2026 · cited 10 timesOpen accessclinical trial, phase iii, multicenter study
- Risdiplam in Presymptomatic Spinal Muscular Atrophy.
Finkel RS, Servais L, Vlodavets D, Zanoteli E, Mazurkiewicz-Bełdzińska M, Jong YJ, Navas-Nazario A, Al-Muhaizea M, Araujo APQC, Nelson L, Wang Y, Jaber B, Gorni K, Kletzl H, Palfreeman L, Rabbia M, Summers D, Gaki E, Wagner KR, Fontoura P, Farrar MA, Bertini E, RAINBOWFISH Study Group. · N Engl J Med · 2025 · cited 19 timesclinical trial, phase ii, multicenter study
- Safety and effectiveness of risdiplam in adults with spinal muscular atrophy: a systematic review.
Alonge P, Urbano G, Gadaleta G. · J Neurol · 2025 · cited 6 timesOpen accesssystematic review, review-article
- Global Prevalence of Spinal Muscular Atrophy in 204 Countries and Territories, 1960-2024: A Systematic Review and Bayesian Modeling Study.
Jeong YD, Son Y, Jeon S, Lee K, Kim HJ, Hwang Y, López-Gil JF, Rahmati M, Woo HG, Kang J, Yon DK. · Pediatr Neurol · 2026 · cited 0 timessystematic review
- Combination therapies in spinal muscular atrophy: a systematic review.
Bemanalizadeh M, Heidary L, Dakkali MS, Hadizadeh S, Ahmadbeigi N, Heidari M, Zamani G, Ashrafi M, Mansouri V. · Eur J Pediatr · 2025 · cited 5 timessystematic review
- Proteomic alterations in cerebrospinal fluid of spinal muscular atrophy patients undergoing nusinersen therapy: a systematic review and meta-analysis of potential biomarkers of treatment response.
Alrabadi B, Marouf M, Bandak N, Yassin ARB, Refai Y, Hammad OZ, Nashwan OM, Alomari O. · Neurol Sci · 2026 · cited 0 timesmeta-analysis, systematic review
- Effectiveness and Safety of Nusinersen and Risdiplam in Spinal Muscular Atrophy: A Systematic Review.
Mehrabian A, Auguste P, Grove A, Brown A, Parr J, Patel M, Butt F, Donoghue J, Yousefi M, Parsons J. · Ann Clin Transl Neurol · 2026 · cited 1 timesOpen accesssystematic review, review-article
- Learning outcomes of infants and young children with spinal muscular atrophy type I provided with modified-electric-toy-cars in their natural environment.
Díaz-López CI, Palomo-Carrión R, Ródenas-Martínez M, de-Andrés-Beltrán B, Nilsson L, Coello-Villalón M, López-Muñoz P. · Assist Technol · 2026 · cited 1 timesrandomized controlled trial
- Economic evidence on the cost-effectiveness of newborn screening for spinal muscular atrophy: a systematic review.
Mittal AK, Patel M, Sharma P, Shekhawat DS, Amrit P, Saini L, Singh K. · Eur J Pediatr · 2025 · cited 3 timessystematic review
- Efficacy and safety of risdiplam in patients with type 1 spinal muscular atrophy: a 3-year open-label extension of the two-part, phase 2 FIREFISH trial.
Mazurkiewicz-Bełdzińska M, Servais L, Baranello G, Boespflug-Tanguy O, Day JW, Deconinck NP, Klein A, Masson R, Mercuri EM, Rose KJ, Vlodavets DV, Xiong H, Zanoteli E, El-Khairi M, Gaki E, Kuthiala M, Gorni K, Kletzl H, Palfreeman L, Darras BT, FIREFISH Study Group. · Lancet Child Adolesc Health · 2026 · cited 1 timesclinical trial, phase ii, multicenter study
- Economic evaluations of disease-modifying therapies for spinal muscular atrophy: a systematic literature review.
Yousefi M, Mehrabian A, Brown A, Butt F, Donoghue J, Parr J, Patel M, Grove A, Parsons J, Auguste P. · Orphanet J Rare Dis · 2025 · cited 3 timesOpen accesssystematic review, review-article
- The impact of early powered mobility training in families and children with Spinal Muscular Atrophy Type I.
Díaz-López CI, Palomo-Carrión R, Coello-Villalón M, Ródenas-Martínez M, Pacheco-da-Costa S, Romay-Barrero H, López-Muñoz P. · Assist Technol · 2026 · cited 3 timesrandomized controlled trial
- Swallowing and feeding after disease-modifying treatment for spinal muscular atrophy: a systematic review of assessment modalities and outcomes.
Martí Y, Gorni K, Kumari S, Mahajan A, Baranello G, Waele L, McGrattan KE. · Orphanet J Rare Dis · 2026 · cited 2 timesOpen accesssystematic review, review-article
- Salbutamol in 5q spinal muscular atrophy: a systematic review and meta-analysis of efficacy and safety.
Xing X, Zhao S, Jiang R, Jiang W. · Eur J Pediatr · 2025 · cited 4 timesmeta-analysis, systematic review
- Electrophysiological assessment of motor unit loss in adult spinal muscular atrophy types III and IV: a multicenter national study comparing MUNIX, CMAP, and MUSIX.
Sole-Cruz E, Salort-Campana E, Lenglet T, Fortanier E, Pereon Y, Berling E, Beloribi-Djefaflia S, Bouhour F, Cintas P, Delmont E, Cavalli M, Ezaru A, De La Cruz E, Fernandes S, Kaminsky AL, Kouton L, Magot A, Nadaj-Pakleza A, Tard C, Pegat A, Nicolas G, Stojkovic T, Hogrel JY, Attarian S. · J Neurol · 2026 · cited 0 timescomparative study, clinical trial
- Effects of physical therapy on motor ability in patients with spinal muscular atrophy III: a study protocol for a randomised controlled trial.
Zhang J, Wang B, He J, Zhu L, Dong X. · BMJ Open · 2025 · cited 1 timesOpen accessclinical trial protocol
- Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial.
Proud CM, Vũ DC, Wilmshurst JM, Sanmaneechai O, Gulati S, Xiong H, Moreno HC, Tay SKH, Thong MK, Born AP, Banzzatto Ortega A, Jong YJ, Al-Muhaizea MA, Lee AW, Visootsak J, Tauscher-Wisniewski S, Alecu I, Parlikar R, Finkel RS, STEER Study Group. · Nat Med · 2026 · cited 16 timesOpen accessclinical trial, phase iii, multicenter study
- Surgical success of subcutaneous systems for intrathecal nusinersen delivery in spinal muscular atrophy: A systematic review and meta-analysis.
Lu VM, Vazquez S, Roach CS, Niazi TN. · Clin Neurol Neurosurg · 2025 · cited 1 timesmeta-analysis, systematic review
- The RESISTANT study (Respiratory Muscle Training in Patients with Spinal Muscular Atrophy): results of a randomized controlled trial.
Kant-Smits K, Bartels B, van Eijk RPA, Asselman FL, Veldhoen ES, van der Ent K, van der Pol WL, Hulzebos EHJ. · Physiotherapy · 2025 · cited 1 timesresearch support, non-u.s. gov't, randomized controlled trial
- Systematic review for economic evaluations on newborn screening for spinal muscular atrophy.
Pace AC, Poon C, Chakraborty P, Oskoui M, McMillan H, Mackenzie A, Round J. · J Neuromuscul Dis · 2025 · cited 2 timesOpen accesssystematic review, review-article
- Myostatin Modulation in Spinal Muscular Atrophy: A Systematic Review of Preclinical and Clinical Evidence.
Gnazzo M, Pisanò G, Baldini V, Giacomelli G, Scullin S, Piccolo B, Turco EC, Esposito S, Pera MC. · Int J Mol Sci · 2025 · cited 0 timesOpen accesssystematic review, review-article
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.